US RE50218

I'll search for authoritative information on this specific reissue patent.

Let me search for the CAFC litigation and the actual claim set.

Let me search specifically for CAFC 2026 docket activity and the exact claim text.

US RE50218 E1 — Verified Summary

Important scope note: My searches were general web/patent-database searches (Google Patents, Orange Book–derived databases, court records). I did not obtain a direct PatentCenter/PTAB feed, and — as detailed below — I found no 2026 CAFC docket involving RE50218. Where I rely on secondary sources I say so.

Bibliographic data (high confidence; corroborated across multiple sources)

Orange Book listing: RE50218 is the sole listed patent for BROMSITE (bromfenac sodium ophthalmic solution 0.075%, NDA 206911, Sun Pharm, approved 2016‑04‑08), use code U‑1834, "treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery." (drugpatentwatch.com; drugfuture.com; drugs.com)

Abstract (verbatim, as fetched)

"The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye."

Subject matter in one paragraph

The reissue is directed to topical ophthalmic (eye‑drop) formulations of the NSAID bromfenac combined with a "flowable mucoadhesive polymer" — defined as a lightly cross‑linked carboxy‑containing polymer such as polycarbophil or the DuraSite® system. The formulation has a low viscosity in the bottle (for drop administration) but gels on contact with tear fluid, giving sustained release and, per the specification, unexpectedly high bromfenac absorption/retention in the aqueous humor, enabling once‑daily (or less frequent) dosing vs. the twice‑daily Xibrom® regimen. The specification also discloses combination embodiments (e.g., bromfenac + ketorolac ± steroidal/antibacterial/other actives), a method of treatment, and kits. Example formulations (Tables 1–3) use polycarbophil (Noveon® AA‑1), citrate buffer, EDTA, NaCl, mannitol, benzalkonium chloride and Poloxamer 407, adjusted to pH 8.3.

Independent claims — plain language

Caveat on authority: the full patent text supplied to me contains the description but not the claims section, and I could not retrieve the claims verbatim from the USPTO. The following is reconstructed from (a) a 2026 district‑court complaint analysis quoting claim 1, and (b) a partial dependent‑claim listing — treat as reliable but not verbatim‑verified for every claim.

1. Claim 1 (composition, independent) — quoted in the 2026 complaint:
   "A topical ophthalmic composition formulated for application to the eye, said composition comprising a therapeutically effective amount of bromfenac and a flowable cross‑linked carboxy‑containing polycarbophil mucoadhesive polymer, wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5, wherein the viscosity is measured with a Brookfield cone and plate viscosity DV‑II+ with the spindle No. CP‑52 at 6 rpm."
   (Source: complaint analysis for D.N.J. 3:26‑cv‑04286. Note the 1,000–3,400 cps / CP‑52-at‑6‑rpm language tracks the specification's alternative viscosity definition — a strong indication this is reissue claim text rather than original '999 claim text.)

2. Further independent composition claims (believed to be claims 10, 12, 13, 14): each an ophthalmic composition/composition‑type claim to which later dependent claims (25–31, 32–37, 38–43…) refer back, variously narrowing the mucoadhesive polymer amount, viscosity, pH, osmolality and bromfenac loading.

3. Independent method claims (believed to be claims 19 and 20): a method for therapeutic treatment of an inflammatory condition of the eye in a mammal, comprising administering the bromfenac/flowable‑mucoadhesive‑polymer ophthalmic composition. Dependents 21–22 enumerate the inflammatory conditions (surgical trauma, dry eye, conjunctivitis, blepharitis, anterior uveitis, cataracts, contact‑lens inflammation, corneal conditions, glaucoma, ocular tumors, oculoplastic conditions, refractive‑surgery conditions, retinal conditions, etc.) and dependents recite specific retinal conditions (AMD, CMV retinitis, diabetic retinopathy/macular edema, CME, retinal detachment, ROP, retinitis pigmentosa, Stargardt's, uveitis, etc.).

4. Dependent claim examples (corroborated): osmolality about 10–400 mOsm/kg and, in one claim, about 290 mOsm/kg at pH about 8.3; bromfenac 0.045%–0.09% w/w; polymer 0.5%–1.5% w/w; viscosity 1,000–2,000 cps. (drugpatentwatch.com/p/patent-claims/RE50218)

Claims appear to run to at least claim 43 (dependent‑claim numbering visible up to 43).

Litigation — and the CAFC question you specifically asked about

• No CAFC 2026 docket for RE50218 was found. Repeated searches of Federal Circuit 2026 opinions/orders, summary digests and dockets returned no appeal, petition, or mandate naming RE50218 or RE50,218. If an appeal exists, I could not locate it and cannot confirm it.
• Most recent district‑court activity (2026): Sun Pharmaceutical Industries Ltd v. Solaris Pharma Corp., D.N.J. No. 3:26‑cv‑04286, complaint filed 2026‑04‑22, following a Solaris Paragraph IV notice letter dated 2026‑03‑11 concerning ANDA No. 220440 for generic bromfenac ophthalmic solution 0.075%. The complaint asserts infringement of the '218 patent generally (without specifying claims) under 35 U.S.C. § 271(e)(2). (ai‑lab‑cl‑prod case analysis)
• Earlier, related history: the predecessor patent 8,778,999 was litigated in D.N.J. No. 3:18‑cv‑02213‑FLW‑TJB, including an Order Vacating Opinion and Order dated 2022‑02‑08 and a motion for reconsideration filed 2021‑10‑28 (these documents appear in the '218 reference list). Solaris was also a defendant in Valeant Pharmaceuticals North America LLC v. Solaris Pharma Corp., D.N.J. No. 3:18‑cv‑13695. A previously approved generic (bromfenac sodium, SENTISS, 2014‑01‑22) and a Lupin ANDA 211239 approved 2024‑02‑02 also exist.
• Note the timing symmetry: the reissue application was filed 2022‑04‑22, shortly after the Feb. 2022 vacatur order in the '999 litigation — consistent with a reissue pursued in connection with (or following) that litigation, but I have not confirmed the reissue's stated purpose/error from the reissue file.

Explicit uncertainties

1. Claims verbatim: I could not verify the exact text/numbering of claims 2–22 from an authoritative source. Claim 1 as quoted is from a litigation document, not from the published reissue.
2. Expiration date conflict: Orange Book/drugs.com show 2029‑03‑05; Google Patents shows adjusted expiration 2029‑08‑07. Google Patents also lists the prior‑art date as 2009‑03‑05. I have not resolved which controls.
3. "About 1,000 to about 3,400 cps" vs. "1,000 to 2,000 cps": dependent claims recite 1,000–2,000 cps while claim 1 (per the complaint) recites up to 3,400 cps; the 3,400 cps / CP‑52 figure appears in the specification only as an alternative measurement, which is notable for any reissue‑added‑matter or recapture analysis.
4. CAFC: absence of evidence here is not proof of absence; I simply could not find any 2026 Federal Circuit matter tied to RE50218.

Key URLs: https://patents.google.com/patent/USRE50218E1/en · https://www.drugpatentwatch.com/p/patent/RE50218 · https://www.drugs.com/availability/generic-bromsite.html · https://ai-lab-cl-prod.azurewebsites.net/case/dct/njd/3:26-cv-04286/doc/analysis/1 · https://pubchem.ncbi.nlm.nih.gov/patent/US-RE50218-E

I'll research litigation involving US patent RE50218 using multiple targeted searches.

The PubChem result reveals a specific case number. Let me dig into that and related matters.

I have strong leads. Let me verify the most recent litigation and check for any other cases, including Federal Circuit appeals.

Bottom line

US Patent RE50218 (US RE50,218 E1, "Non-Steroidal Anti-Inflammatory Ophthalmic Compositions," issued Nov. 26, 2024, assignee Sun Pharmaceutical Industries Ltd.) has exactly one known litigation to date: a Hatch‑Waxman ANDA case filed April 22, 2026 against Solaris Pharma Corporation in the District of New Jersey. It is pending. There is also one closely-related, now-dismissed case that was litigated on the parent patent (US 8,778,999, of which RE50218 is the reissue), which I summarize separately because it is the same patent family, same inventors, and same product — but it is not literally RE50218 litigation.

I found no Federal Circuit appeal, no PTAB IPR/PGR, no ITC investigation, and no other district court case naming RE50218.

Case asserting RE50218

Key relief sought: entry of judgment that submission of ANDA No. 220440 infringes the '218 patent; an order under § 271(e)(4)(A) setting the ANDA approval date no earlier than patent expiry; a permanent injunction under § 271(e)(4)(B)/§ 283; declaratory judgment of future infringement; damages; and an exceptional-case finding under § 285.

Sources:

• https://dockets.justia.com/docket/new-jersey/njdce/3:2026cv04286/[596376](/patent/596376)
• https://www.courtlistener.com/docket/73232398/sun-pharmaceutical-industries-ltd-v-solaris-pharma-corporation/
• Complaint (PDF): https://ia801601.us.archive.org/12/items/gov.uscourts.njd.[596429](/patent/596429)/gov.uscourts.njd.596429.1.0.pdf
• https://www.robinskaplan.com/printpilot-publication-generically-speaking-hatch-waxman-bulletin-2026-q2-new-anda-cases.pdf
• https://www.drugpatentwatch.com/p/litigation/patent/RE50218

Numbering note (no auto-correction): CourtListener and the complaint PDF header both render the case as 2:26-cv-04286-EP-SDA, while Justia, the Robinson+Kaplan ANDA bulletin, and the ParagraphFour tracker render it as 3:2026cv04286, Judge Padin, D.N.J. I am reporting both as they appear rather than harmonizing them; the two docket numbers refer to the same April 22, 2026 Sun v. Solaris complaint. DrugPatentWatch's litigation page also displays the patent as "RE5218" in its title field; the page is keyed to RE50218 (the only case listed on it is the Solaris case above).

Related litigation on the parent patent (US 8,777,999) — context only, not RE50218

This matters directly to RE50218 because the reissue application (US 17/726,665, filed April 22, 2022) appears to have followed immediately on the heels of the vacatur, and the reissue claim 1 as published adds the measurement limitation — "wherein the viscosity is measured with a Brookfield cone and plate viscosity DV-II+ with the spindle No. CP-52 at 6 rpm" — which speaks directly to the indefiniteness holding. (Compare the claim text at https://www.drugpatentwatch.com/p/patent-claims/RE50218 with the '999 claim 1 quoted in the 2021 opinion.)

Sources:

• https://law.justia.com/cases/federal/district-courts/new-jersey/njdce/3:2018cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/
• https://www.courtlistener.com/docket/[6668689](/patent/6668689)/sun-pharmaceutical-industries-ltd-v-lupin-limited/
• https://www.robinskaplan.com/newsroom/insights/sun-pharma-global-v-lupin
• https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/211239Orig1s000ltr.pdf
• https://pubchem.ncbi.nlm.nih.gov/patent/US-RE50218-E (lists the vacatur order and reconsideration brief as litigation documents for the '218 patent)

Caveats on this related case: (a) The Feb. 8, 2022 vacatur means there is no surviving merits adjudication of the '999 patent; the 2021 invalidity findings should not be treated as current law. (b) ParagraphFour's tracker describes the case as "Settled and dismissed 2/3/20," which conflicts with the Sept. 30, 2021 opinion and the March 2021 trial in the same docket; the 2020 date most plausibly reflects an administrative termination/closure that the parties later reopened (the opinion itself notes the parties "attempted to settle in 2020" and "were unable to do so"). I am flagging the discrepancy rather than resolving it.

Other bromfenac litigation I checked and excluded

• Senju Pharmaceutical Co., Ltd., Bausch & Lomb, Inc. and Bausch & Lomb Pharma Holdings Corp. v. Lupin Ltd. and Lupin Pharmaceuticals, Inc., No. 1:14-cv-00667 (D.N.J.) and v. Metrics, Inc. et al., No. 1:14-cv-03962 (D.N.J.) — these involve the bromfenac '431 patent, a different patent, not RE50218.
• Valeant Pharmaceuticals North America LLC et al. v. Solaris Pharma Corp., No. 3:18-cv-13695 (D.N.J.) — cited in the Solaris complaint only for personal jurisdiction; unrelated patent.

What I could not confirm

• No Federal Circuit appeal by either Sun or Lupin from the 3:18-cv-02213 proceedings was located. Given the Feb. 8, 2022 vacatur, an appeal would in any event have been unlikely.
• No PTAB proceeding (IPR, PGR, derivation, or reissue-related contested case) naming RE50218 appeared in any source I checked. The reissue itself was an ex parte prosecution (Application No. 17/726,665), not litigation.
• No lawsuit naming RE50218 against any party other than Solaris Pharma Corporation, including Lupin, despite Lupin's ANDA 211239 approval on Feb. 2, 2024 and the listing of RE50218 in the Orange Book for BromSite (NDA 206911-001) as of the Dec. 26, 2024 submission date. Because the current docket in Sun v. Solaris remains active into August 2026 and new ANDA suits are filed on 45-day clocks, additional RE50218 cases may exist that are not yet indexed in the aggregators I searched. I could not confirm the existence or absence of such filings to a high degree of confidence.
• Ex-US proceedings: Google Patents flags "Family has litigation" for the RE50218 family (family ID 42678805) via Darts‑IP, and the family includes EP 2403493, CA 2753947, ES 2586064, PT 2403493, DK 2403493 and WO 2010102192. I did not verify any specific EPO opposition or national nullity action on those counterparts, and in any event those would not be US litigation involving RE50218.

Analyst note on one search result to disregard: one hit returned in connection with "RE50218" was a Federal Circuit appellee brief in a diamond/PDC matter referencing a "'502 patent" (USS/New Asia/Haimingrun). That is a different patent number and unrelated to RE50218; I have excluded it rather than auto-correcting or conflating the identifiers.

I'll start by checking the structured PTAB block against live sources, then search for any AIA trial activity on this reissue patent.

No AIA proceedings surfaced on the reissue number itself. Let me test the related original patent and the litigation trail, since a reissue's IPR history often sits under the pre-reissue number.

Key context is emerging: the parent patent survived a district-court invalidity judgment that was later vacated, and the reissue application was filed months afterward. Let me confirm whether any PTAB proceeding exists on either the '999 or the RE50218.

Proceedings overview

Total AIA trial proceedings on US RE50218: zero. The USPTO Open Data Portal structured block included in this prompt reports no AIA trial proceedings for this patent, and my independent web searches surfaced no IPR, PGR, or CBM petition ever filed against RE50218 — or against its parent, U.S. Patent No. 8,778,999 (the pre-reissue patent, filed 2009-03-05, issued 2014-07-15, expiring 2029-08-07). So the breakdown is: active 0 / invalidated-by-PTAB 0 / sustained 0 / settled 0 / institution denied 0.

That zero is not the same as "hardened." RE50218 is a reissue granted 2024-11-26 whose parent was held invalid (obvious under § 103 and indefinite under § 112) after a five-day bench trial in Sun Pharma Global FZE v. Lupin Ltd., No. 3:18-cv-02213-FLW-TJB (D.N.J. 2021-09-30) — a judgment that was then vacated by order dated 2022-02-08 and never reviewed by the Federal Circuit. The reissue application was filed 2022-04-22, roughly ten weeks after that vacatur. A defendant today is therefore facing a patent with zero PTAB history, one vacated district-court loss, and a full public trial record of how it was beaten.

No proceeding sections follow — because there are no proceedings.

I will not manufacture proceeding numbers, panels, or FWDs. Instead, here is the closest thing on the record, which you must not mistake for an AIA trial:

Related non-PTAB activity (context, not an AIA proceeding)

• 3:18-cv-02213-FLW-TJB — Sun Pharma Global FZE / Sun Pharmaceutical Industries, Inc. v. Lupin Ltd. / Lupin Pharmaceuticals, Inc. (D.N.J.)

  • Type: Hatch-Waxman ANDA litigation (§ 271(e)(2)), not an AIA trial. No petition number exists.
  • Filed: 2018-02-14/15; five-day remote bench trial 2021-03-22 to 2021-03-26; opinion 2021-09-30 (Chief Judge Freda L. Wolfson).
  • Holding on the parent '999 patent: (1) Lupin's ANDA product does not literally infringe; (2) claims 1, 3, 9, 10, 11, and 16 are obvious in light of U.S. Patent No. 6,159,458 ("Bowman I"); (3) the claim terms mentioning viscosity are indefinite (the specification's Brookfield Method 2 specifies no spin time); (4) no inequitable conduct by Dr. Lyle Bowman, though the court found Bowman I material and the nondisclosure "negligent, possibly grossly negligent."
  • Panel analog: Judge Wolfson, not an APJ panel. Expert witnesses: Dr. Orest Olejnik (Sun), Dr. Justin Hanes and Dr. Daniel Bloch (Lupin).
  • Termination: an Order Vacating Opinion and Order, Feb. 8, 2022 appears in the reissue's file history (it is cited as a document of record against RE50218). This is consistent with a post-trial settlement and vacatur. Verdict: the invalidity adjudication has no preclusive effect on anyone.
  • Appeal: I found no Federal Circuit appeal of the 2021-09-30 judgment and no CAFC opinion on the '999 or RE50218. I flag this as "no evidence found" rather than a verified negative.
  • Links: https://www.courtlistener.com/docket/[6668689/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=6668689-0244)/sun-pharma-global-fze-v-lupin-limited/ · https://law.justia.com/cases/federal/district-courts/new-jersey/njdce/3:2018cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/

• 3:2026-cv-04286 (D.N.J.) — Solaris Pharma Corporation, filed 2026-04-22, listed by Paragraph IV tracking as asserting RE50,218 against BromSite. This is a new district-court assertion of the reissue, not a PTAB filing. If you are counsel on that case (or on the brand side), the § 315(b) one-year clock runs from service of the complaint — for Solaris, likely into 2027.

• Unrelated adjacency: Lupin has been active in IPR against a different bromfenac formulation patent (the "'606 patent," tyloxapol-containing aqueous bromfenac preparations). That PTAB proceeding does not involve RE50218 or the '999 patent — do not cite it as RE50218 activity. Source: PTACTS petition document, https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1462075](/patent/1462075)

Strategic summary

Claim status. Nothing on RE50218 is canceled by the PTAB, because nothing was ever challenged there. The reissue claim set is broader in number than the '999 patent's 20 claims — the published claim listing runs at least through claim 35, with new osmolality and pH-dependent dependent claims (e.g., claim 23: "osmolality from about 10 mOsm/kg to 400 mOsm/kg"; claim 24: "osmolality of about 290 mOsm/kg and a pH of about 8.3"; claims 26–35 depending from claims 12–13). Claim 1 of the reissue ("flowable mucoadhesive polymer") is textually broader than claim 1 of the '999 patent ("flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer") — but because the reissue was filed 2022-04-22, more than two years after the '999 patent issued on 2014-07-15, broadening reissue is barred by 35 U.S.C. § 251(d); the claim set must be read as narrowing in net effect, with the added dependent claims carrying the load. I could not verify the exact total claim count or the reissue file-history changes from the sources retrieved, and I will not assert them. Every claim should be treated as UNTESTED until you read the reissue file wrapper at https://patents.google.com/patent/USRE50218E1/en and PAIR.

Estoppel landscape. There is no § 315(e)(2) estoppel on this patent — no petitioner exists, so no one is barred, and no one is protected. That cuts both ways and is the single most important asymmetry here:

• No petitioner estopped → you can raise anything: Bowman I (U.S. Pat. No. 6,159,458), Sawa, Roy, Chandrasekaran, Patel (U.S. Pat. No. 5,340,572), the Xibrom physician labeling, the Bucci 2008 paper — free of IPR-side estoppel.
• No petitioner protected → you are not shielded by anyone else's win. But note that the vacatur means the 2021 judgment gives you no collateral estoppel benefit either; you would have to prove invalidity from scratch. On the other hand, the entire Lupin trial record is public and reusable: Dr. Hanes's obviousness opinions on Bowman I, and the spin-time indefiniteness theory, are transcript-ready and were accepted by a district judge on clear-and-convincing evidence. That is an unusually favorable starting position for a petition — you are drafting against a theory that already won once.

Pattern signals. (1) Same petitioner, multiple IPRs? No — Lupin litigated in district court rather than petitioning, and there is no IPR filer at all. (2) Patent owner aggressive on PTAB appeals? No CAFC appeal found from the '999 case; Sun's strategy instead appears to have been reissue-as-rehabilitation after losing at trial, coupled with settlement/vacatur of the adverse judgment. (3) Defensive aggregator (Unified Patents, RPX, etc.)? No evidence of any aggregated or third-party challenge in the chain. (4) Assertion cadence: '999 asserted 2018; RE50218 asserted 2026 — the reissue is live and being enforced right now, so the risk is current, not historical.

Recommended next steps

1. Treat the absence of PTAB activity as a timing signal, not a comfort. Well-asserted Orange-Book-listed patents normally attract IPRs. This one drew a Hatch-Waxman trial instead (2018), lost at that trial, and returned as a reissue in 2024 and a new suit in 2026. The absence of IPRs reflects a settlement-shaped history, not a hardened patent.
2. Pull the FWD-equivalent — the D.N.J. opinion — and quote it, but cite it carefully. It is a vacated judgment. You may cite the reasoning and the trial record as persuasive/evidentiary material; you may not cite it as a preclusive invalidity determination. The operative link for the opinion is https://www.courtlistener.com/docket/[6668689/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=6668689-0244)/sun-pharma-global-fze-v-lupin-limited/ (CourtListener) and https://law.justia.com/cases/federal/district-courts/new-jersey/njdce/3:2018cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/ (Justia). The disposition language is: "Claims 1, 3, 9, 10, 11, and 16 in the '999 Patent are obvious in light of Bowman I" and "the claim terms mentioning viscosity are indefinite." Those are '999 claims, not reissue claims — do not transplant the numbers.
3. Confirm no petition is pending before you commit to a § 315(e)(2) or § 325(e)(2) theory. Query PTAB E2E directly by both RE50218 and 8,778,999, and by "Bromsite"/"bromfenac" petitioner names (Lupin, Solaris, Sentiss, Bausch, InSite). My searches found nothing; the ODP block reports nothing; PTAB E2E was not directly queryable in this session. If you find a recently filed petition my sources missed, the strategic picture changes materially.
4. PGR and IPR timing windows on the reissue. The § 321(c) PGR window runs nine months from issuance of a reissue; RE50218 issued 2024-11-26, so that window closed on or about 2025-08-26. IPR is available now, subject to the § 315(b) one-year bar from service of any complaint on you. For Solaris (complaint 2026-04-22), the bar date is roughly 2027-04. If you are inside the bar, file early — the PTAB's statutory deadline is an institution decision within 6 months and an FWD within 12 months of institution.
5. Build the petition on the reissue's own weak flank. The new dependent claims add osmolality and pH values (about 290 mOsm/kg, pH about 8.3) that map directly onto the BromSite 0.075% product and its NDA — the same specification and same Bowman I art that already produced a § 103 win. Pair that with a § 112 indefiniteness theory if you can sustain it: the reissue carries forward the same viscosity-parameter language whose spin-time gap the D.N.J. court found indefinite, and § 112 is available in PGR (not IPR), so a § 112 attack against a 2024-issued reissue has limited PTAB vehicles left.
6. Do not overlook reissue-specific defenses. For any product or activity predating 2024-11-26, evaluate absolute and equitable intervening rights under 35 U.S.C. § 252 for reissue claims that were substantively changed in scope. Because the reissue was filed more than two years after the original patent issued, you can also probe whether any claim was impermissibly broadened contrary to 35 U.S.C. § 251(d) — a reissue-specific invalidity defense that has no IPR counterpart.

Sources grounding this memo: https://patents.google.com/patent/USRE50218E1/en · https://www.drugpatentwatch.com/p/patent-claims/RE50218 · https://www.drugpatentwatch.com/p/patent/RE50218 · https://www.robinskaplan.com/newsroom/insights/sun-pharma-global-v-lupin · https://rmmslegal.com/rmms-secures-non-infringement-and-invalidity-win-on-bromsite-bromfenac-ophthalmic-solution-0-075/ · https://pubchem.ncbi.nlm.nih.gov/patent/US-RE50218-E · https://paragraphfour.com/members/gregoryglass/activity/11848/

I'll research this patent's ownership chain carefully. Let me start with parallel searches.

Now let me chase the actual assignment records and litigation history.

Ownership & Assignment Analysis — US RE50,218 E1

Patent: US RE50,218 E ("the '218 patent") — Non-steroidal anti-inflammatory ophthalmic compositions
Reissue application: US 17/726,665, filed 2022‑04‑22; granted 2024‑11‑26
Underlying original patent: US 8,778,999 ("the '999 patent"), app. filed 2009‑03‑05, issued 2014‑07‑15
Current assignee of record: Sun Pharmaceutical Industries Ltd (Mumbai, IN) / Google Patents "Current Assignee"; Orange Book–listed against NDA 206911 (BromSite®)
Family / litigation ID: Darts‑IP family 42678805; Google Patents flags "Family has litigation"

Source limitation up front. The USPTO Assignment Center (assignmentcenter.uspto.gov) was not reachable for record-level retrieval within this session, so I could not capture reel/frame numbers, execution dates, or the correspondent of record for any recording. The chain below is reconstructed from (a) the chain-of-title allegations in the operative Paragraph IV complaint, which recite the assignments verbatim as a jurisdictional predicate, and (b) SEC/press/court records. Where I do not have a reel/frame, I say so rather than guess. Treat every reel/frame field as unverified pending a live Assignment Center pull.

Inventors

All four are consistently associated with the same original assignee; PatentLeaderboard attributes 46 US patents to Lyle M. Bowman at "Insite Vision Incorporated," and Sun Pharma Global FZE's portfolio lists Bowman among its top inventors (5 patents) — a direct spillover from the InSite acquisition.

Unusual patterns / caveats:

• Departure timing is not determinable from the sources available here; I found no evidence of an inventor exodus within 12 months of the 2009 filing. The inventors' assignment to InSite Vision is recited in the D.N.J. complaint ("each of whom assigned their interest in the '999 patent to InSite Vision Incorporated") — so no orphaned inventor share.
• Non-standard inventor profile: Dr. Bowman was both a named inventor and the attorney/agent who prosecuted the application. This mattered materially — it became the inequitable-conduct theory (failure to disclose his own earlier Bowman I patent, US 6,159,458) in Sun Pharma Global FZE v. Lupin Ltd., and was also the source of the successful obviousness attack. Flagging this because an inventor-prosecutor who is later cross-examined is a litigation-fragility signal, not an NPE signal.

Original assignee

InSite Vision Incorporated (Alameda, California) — specialty ophthalmic drug-delivery company; developer of the DuraSite® polymer platform. It did ship a product embodying the claims: it filed NDA 206911 for BromSite® (bromfenac ophthalmic solution 0.075%) on 2015‑06‑10, using the DuraSite® polycarbophil vehicle claimed here.

• Primary line of business: branded specialty ophthalmics and ophthalmic drug delivery (AzaSite®, Besivance® partnerships; DuraSite/DuraSite2 platforms).
• Status: acquired, not dissolved/bankrupt. Sun Pharma announced its acquisition on 2015‑09‑15 via an indirect wholly-owned subsidiary; the tender offer closed November 2015 at US$0.35/share (≈US$48M equity value). Notably, InSite had a competing, already-signed merger with another bidder (QLT Inc.) that was terminated in favor of Sun's superior offer — i.e. a bidding contest, not a distressed sale. InSite's own financials at the time (H1 2015: US$3.8M revenue, US$7.5M net loss) show a cash-burning but operating, not insolvent, company.

Assignment timeline

Chain of title as recited in Sun Pharmaceutical Industries Ltd v. Solaris Pharma Corp., No. 3:26‑cv‑04286 (D.N.J.), ¶¶19–21, corroborated by the 2018 D.N.J. opinion and Sun press releases. Reel/frame not retrieved for any entry.

• 2009‑03‑05 (app. filing) / recorded at issuance — Reel not retrieved

  • Conveyance: Assignment (inventor → employer), recited in complaint ¶19
  • Assignor: Kamran Hosseini, Lyle Bowman, Erwin C. Si, Stephen Pham
  • Assignee: InSite Vision Incorporated (Alameda, CA)
  • Correspondent: not retrieved (would be on the '999 face/assignment record; InSite's patent counsel of record not confirmed in this session)
  • Context: Standard employment/obligation assignment at filing.

• 2016‑03 (executed, per D.N.J. opinion: "pursuant to a March 2016 agreement with Insite Vision Inc., the original assignee") / recorded not retrieved — Reel not retrieved

  • Conveyance: Assignment (post-acquisition asset transfer)
  • Assignor: InSite Vision Incorporated
  • Assignee: Sun Pharma Global FZE (Jebel Ali Free Zone, UAE — Sun Pharma's NDA holder of record for BromSite®, NDA 206911)
  • Correspondent: not retrieved. Recurrence check not possible without the record; this is exactly the field the Assignment Center pull would resolve.
  • Context: Acquisition / post-merger asset rationalization — InSite was acquired Nov 2015 and its ophthalmic IP was moved up to the Sun Pharma FZE holding/NDA entity.

• 2021‑08‑31 (NCLT Ahmedabad approval) / 2021‑10‑01 (effective) / recorded not retrieved — Reel not retrieved

  • Conveyance: Merger / Scheme of Amalgamation (by operation of law; possibly recorded as Merger or Change of Name)
  • Assignor: Sun Pharma Global FZE
  • Assignee: Sun Pharmaceutical Industries Ltd ("Sun India")
  • Correspondent: not retrieved
  • Context: Internal corporate reorganization only — the UAE subsidiary was amalgamated into the Indian listed parent, transferring all rights and obligations including the '999 patent. No change in ultimate control.

• 2022‑04‑22 (reissue application filed) / 2024‑11‑26 (RE50,218 granted) — Reel not applicable (prosecution event, not an assignment)

  • Applicant/owner of record: Sun Pharmaceutical Industries Ltd
  • Context: Reissue prosecuted by the then-owner; no new assignment. Complaint ¶21 states the inventors "assigned their interest in the '218 patent to Sun India."

No further transfers recorded to date. The reissue issued to Sun India and Sun India is the party suing on it.

Timeline diagram

timeline
    title Ownership of US RE50218 E1
    2009 : Filed 2009-03-05 by InSite Vision
    2014 : US 8778999 issued 2014-07-15
    2015 : Sun Pharma to acquire InSite Vision
         : Tender offer at 0.35 dollars per share
    2016 : Patent assigned to Sun Pharma Global FZE
         : BromSite approved 2016-04-08
    2021 : Global FZE merged into Sun India
         : Merger effective 2021-10-01
    2022 : Reissue application filed 2022-04-22
    2024 : RE50218 E1 granted 2024-11-26
    2026 : Sun India sues Solaris over RE50218

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The only non-inventor transfers are to (i) Sun Pharma Global FZE, which is the FDA NDA holder of record for BromSite® (NDA 206911) — an operating pharmaceutical entity, not a bare licensing vehicle; and (ii) Sun Pharmaceutical Industries Ltd, a publicly listed, revenue-generating multinational (top-5 global generic manufacturer, US and India listed). No "IP / Licensing / Holdings / Ventures" suffix LLC, no registered-agent-only address, no single-member Delaware/Texas LLC anywhere in the chain.

2. Known asserter in the chain — NOT PRESENT.
No assignee in the chain matches Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, or any Spangenberg entity. Current assignee is a brand pharmaceutical manufacturer, not an NPE. The Stanford NPE Patent Litigation Database lists RE50218, but that reflects litigation involvement/entity classification datasets generally, not an NPE owner — the plaintiff is Sun India. I could not independently verify Sun's absence from Unified Patents/RPX "high-frequency plaintiff" lists in this session; no evidence of listing was found.

3. Repeat correspondent across the chain — UNCLEAR (data gap).
I could not retrieve the correspondent of record for any of the three recordings. The entire point of this signal is recurrence, which cannot be assessed without the reel/frame data. This is the single highest-value item to retrieve on a live Assignment Center pull, because the chain has three recordings by three different Sun-family entities and a repeat prosecution/recording firm across all three would be the classic tell (here it would almost certainly resolve exculpatory — large pharma routinely uses one outside IP firm, and Sun's recording agent would be traceable to Sun's regular patent counsel).

4. Cascading transfers — NOT PRESENT.
Three recordings across a ~12-year span (2009/2016/2021), with the two post-issuance transfers five years apart. No chained LLC cascade, no transfers inside 24 months of each other, no shared registered-agent address pattern.

5. Pre-litigation transfer — NOT PRESENT.
The last title event (the 2021 merger into Sun India) preceded the first RE50218 suit (Sun v. Solaris, No. 3:26‑cv‑04286, filed 2026‑04‑22) by ~4.5 years. There is no assignment within 6 months of the 2026 filing. Contrast with the typical NPE setup, where a patent is moved into an assertion vehicle weeks before the complaint.

6. Bankruptcy fire-sale — NOT PRESENT.
InSite Vision was bought out at a premium in a contested tender offer (competing QLT merger terminated); there was no Chapter 7/11, no §363 sale, no bankruptcy court order. No Kodak/Nortel/Polaroid-style fact pattern.

7. Privateering — NOT PRESENT.
The operating company did not hand the patent to a third-party NPE to assert on its behalf. Sun itself is the plaintiff in the Hatch‑Waxman actions (2018 against Lupin as Sun Pharma Global FZE; 2026 against Solaris as Sun India). This is direct, named-party enforcement by the product owner.

8. Defensive aggregator — NOT PRESENT.
No RPX / AST / LOT / Unified / OIN entity appears anywhere in the chain. (Inverse signal not met — but also harmless, since the patent is being actively asserted, not neutralized.)

Adjacent finding worth recording (not an NPE signal, but it explains the reissue): In Sun Pharma Global FZE v. Lupin Ltd., No. 3:18‑cv‑02213‑FLW‑TJB (D.N.J.), the court held on 2021‑09‑30 that the '999 patent was not literally infringed, obvious over Bowman I (US 6,159,458), and indefinite for failing to specify a spin time for the viscosity measurement (2021 WL 4473411). The record then shows an Order Vacating Opinion and Order dated 2022‑02‑08, and the reissue application was filed 2022‑04‑22 — i.e. Sun's response to the invalidity ruling was to reissue, not to reassign. RE50,218 claim 1 now expressly recites "wherein the viscosity is measured with a Brookfield cone and plate viscosity DV-II+ with the spindle No. CP-52 at 6 rpm," which directly cures the indefiniteness finding. Sophisticated prosecution-side repair by the operating owner; the opposite of a monetization-by-transfer pattern.

Verdict

Operating-company assertion.

Sun Pharmaceutical Industries Ltd — a revenue-generating, publicly listed brand/generic pharmaceutical manufacturer that holds NDA 206911 and commercializes BromSite® (bromfenac ophthalmic solution 0.075%) in commerce — is the current owner and the named plaintiff asserting RE50,218 against generic ANDA filers (Solaris Pharma, ANDA 220440; previously Lupin, ANDA 211239) in standard Hatch‑Waxman §271(e)(2) actions. The chain runs entirely inside a corporate family (InSite Vision Incorporated → Sun Pharma Global FZE per the March 2016 agreement recited in D.N.J. No. 3:26‑cv‑04286 ¶19 → Sun Pharmaceutical Industries Ltd by the 2021‑08‑31 NCLT‑approved / 2021‑10‑01 effective Scheme of Amalgamation), with no shell LLC, no known NPE, no sub‑24‑month cascade, no bankruptcy sale, and no pre‑litigation transfer. The signal I could not close out is repeat correspondent (unclear) — a live Assignment Center pull for all three recordings on this patent is the one remaining verification step, and on the current evidence it is expected to resolve toward Sun's regular patent counsel rather than an NPE agent.

Verify at: USPTO Assignment Center — search patent number RE50218 (or the underlying 8,778,999) at https://assignmentcenter.uspto.gov/ ; mirrored at https://assignment.uspto.gov/patent/index.html . Cross-check the reissue file wrapper at USPTO PatentCenter for application 17/726,665.

Confidence & open items

• High confidence: identity of all four inventors; InSite Vision as original assignee; the Nov 2015 acquisition; the March 2016 FZE assignment; the Oct 2021 merger into Sun India; current assignee Sun India; operating-company (non‑NPE) status; the 2018 Lupin outcome and the 2026 Solaris filing.
• Not established (explicitly): all reel/frame numbers, all execution and recording dates as recorded, and every correspondent-of-record entry. I have deliberately left these blank rather than supply plausible-looking values. If you need the reel/frame citations and correspondent names for a chart or filing, the Assignment Center query above will produce them deterministically.

I'll search for the specific patent RE50218 and its cited prior art references.

Let me get the citation tables specifically from the patent's Google Patents page and PubChem record.

Let me try to retrieve the actual citation table from the patent's records.

Prior Art Analysis — U.S. Patent RE50218 (RE50218E1)

1. Identification of the patent under analysis

Legal framework note: Because the underlying application has a 2009-03-05 priority date (pre-March 16, 2013), the pre-AIA 35 U.S.C. §§ 102(a), (b), (e), (g) and § 103(a) govern. A reissue takes the filing date of the original patent for prior-art purposes.

Search-coverage caveat (stated plainly): I was able to retrieve the patent's full specification, classification, family and reissue-prosecution reference list, but I was not able to retrieve a verbatim image of the front-page "References Cited" table / PTO-892 from the 17/726,665 file wrapper in this session. The references below are those (i) expressly cited within the RE50218 specification (incorporated by reference), and (ii) appearing in the published "documents considered" list of record for this patent as reflected in the published record (alphabetical A–N portion retrieved). Any title/assignee I could not verify is marked accordingly. Verify against USPTO PatentCenter before relying on it in a filing.

2. Patent references cited within RE50218 (all expressly incorporated by reference)

3. Non-patent literature cited in the specification

4. Further references of record in the RE50218 reissue prosecution (retrieved list, alphabetical A–N; examiner/submitted "documents considered")

Source: PubChem patent record for US-RE50218-E (https://pubchem.ncbi.nlm.nih.gov/patent/US-RE50218-E). This is the published reference list attached to the patent; the retrieved extract runs alphabetically from "Jack DeRuiter…" through "Nathan Congdon…," so later entries (O–Z) and the U.S. patent-citation block were not returned.

Representative entries and their § 102/§ 103 significance:

Bottom line on § 102 for this group: none of the retrieved NPL items, standing alone, discloses all elements of any independent claim of RE50218 (bromfenac free acid at 0.045–0.09% w/w and a flowable mucoadhesive carboxy polymer at 0.5–1.5% w/w in an aqueous drop formulation at pH ≈ 8.3 / 1,000–2,000 cps, with recited aqueous-humor retention). They operate as § 103 art, individually or in combination, not as § 102 anticipation.

5. Highly relevant references that surfaced but are not confirmed to appear on the RE50218 face

Flag these as candidates to check against the actual PTO-892 / IDS in the 17/726,665 file:

6. Mapping of cited art to the claim sets (as identified from the published claim listing)

Independent claim groups in the granted reissue (claim numbering as reflected in the published claim listing): claim 1 (ophthalmic composition), claim 10 and claims 12–18 (sustained-release bromfenac delivery systems), and claims 19–22 (methods of therapeutic treatment), with dependent claims through at least claim 44 (e.g., claim 23 osmolality 10–400 mOsm/kg; claim 24 osmolality ≈290 mOsm/kg + pH 8.3; claims 25/31/37/43 bromfenac 0.045–0.09%; claims 26/32/38 polymer 0.5–1.5%; claims 27/33/39 viscosity 1,000–2,000 cps; claims 28/34/40 pH 8.3).

7. Conclusions

1. No reference cited in RE50218 appears to anticipate any claim under pre-AIA § 102. The cited patent art bifurcates cleanly: bromfenac art (US 4,910,225 / Ogawa) supplies the active ingredient; DuraSite/polycarbophil art (US 5,192,535 to Davis et al., plus the Brown and Mueller cross-linker patents) supplies the vehicle. Neither side of that bifurcation, taken alone, discloses the claimed combination.
2. The cited art is best characterized as § 103(a) material, and the highest-value combination targets are: (a) Davis '535 + US 4,910,225 (bromfenac ophthalmic solution) + an NSAID-in-mucoadhesive-polymer reference; and (b) the same combination further in view of Bucci (2008) for the once-daily dosing rationale.
3. The pH ≈ 8.3 / osmolality ≈ 290 mOsm/kg limitations (claims 24, 28, 30, 34, 36, 40, 42) are the least well covered by the cited art, because Davis '535 discloses pH 3.0–6.5 — an in-situ-gelling (low-pH) regime, whereas RE50218 claims a near-physiological basic pH. Expect a challenger to argue this is merely an optimization; expect the patentee to argue unexpected aqueous-humor retention (the FIG. 1A/1B data vs. Xibrom®).
4. JP 4158203 B2 ("Non-steroidal anti-inflammatory ophthalmic suspension," which itself cites Davis '535 and describes an NSAID in a lightly cross-linked carboxy polymer suspension) is, in my assessment, the single most dangerous uncited-to-me reference and should be checked immediately against the 17/726,665 file wrapper.
5. Because RE50218 is a reissue, § 251 also matters: if the reissue claims were broadened relative to the original patent, intervening-rights and recapture questions arise in addition to § 102/103. Recover the original patent number from PatentCenter before finalizing a validity opinion — I could not confirm it in this session and will not guess.

Unverified items I am explicitly flagging: (i) the exact front-page "References Cited" list of RE50218 and the PTO-892 of application 17/726,665; (ii) the bibliographic details (issue dates, titles, assignees) of US 4,910,225, US 2,798,053, US 4,192,827, US 4,136,250 and US 4,548,990; (iii) the exact identity of the original (pre-reissue) U.S. patent; (iv) the O–Z portion of the non-patent-literature list and the U.S.-patent citation block; (v) whether JP 4158203 B2, Sallmann '343 or the Senju/Bucci art is formally of record in RE50218. Recommended next step: pull the PatentCenter "References Cited" and "Documents" tabs for reissue application 17/726,665 (https://patentcenter.uspto.gov) to close these gaps.

I'll ground this analysis with targeted searches before drawing conclusions.

Let me identify the original (pre-reissue) patent and its cited prior art.

Let me pull the actual claim set of RE50218 and the key prior-art references (including Bowman I, which was litigated against the parent patent).

Scope note before the analysis

Two transparency points, because they affect how much weight the analysis can bear:

1. The fetched RE50218 page text I was given does not contain a discrete, labelled "Prior Art" section. The prior-art-related content on that record consists of (a) the "Prior art keywords" field — composition, eye, agent, bromfenac, ophthalmic composition — and (b) the reference list captured against the RE50218 record (Google Patents/PubChem "Citations"), plus the references the specification expressly incorporates. I use those, and flag anything I could not verify. The consolidated list is at https://pubchem.ncbi.nlm.nih.gov/patent/US-RE50218-E (Section 12, "Citations").
2. The fetched page text omits the claim set. I therefore quote (i) the parent-claim language verbatim from US 8,778,999 ("the '999 patent"), which RE50218 reissues, and (ii) the RE50218 claim fragments retrievable from https://www.drugpatentwatch.com/p/patent-claims/RE50218. I have not silently reconstructed any claim.

1. The patent and the legal frame

• RE50218 (filed 2022‑04‑22 as 17/726,665; granted 2024‑11‑26; priority 2009‑03‑05; assignee Sun Pharmaceutical Industries Ltd; listed against BROMSITE, NDA 206911) is a reissue of US 8,778,999 — same title, same four inventors (Hosseini, Bowman, Si, Pham), same 2009‑03‑05 priority. The '999 patent was filed 2009‑03‑05, issued 2014‑07‑15, expiry listed 2029‑08‑07 (Orange Book listing shows RE50218 at 2029‑03‑05). See https://www.drugpatentwatch.com/p/patent/RE50218 and https://www.drugfuture.com/fda/drugview/206911. (This parentage is a high-confidence inference from identical title/inventors/priority/assignee and the surrendered-'999 Orange Book history — I did not retrieve the reissue certificate itself, so treat it as inference, not record fact.)
• Pre‑AIA §103(a) governs (effective filing date 2009‑03‑05, i.e., before 2013‑03‑16). Prior art = what a POSITA had before 2009‑03‑05. The Graham v. John Deere / KSR framework applies: scope and content of the art, differences from the claims, PHOSITA level, and objective indicia.
• Reissue constraint (35 U.S.C. §251(d)): because the reissue was applied for ~8 years after the '999 grant (2014‑07‑15), it may not enlarge claim scope. RE50218's claims are therefore at most coextensive with — and are visibly narrower than — the '999 claims. That matters: the obviousness analysis of the '999 claim scope is the outer boundary of anything RE50218 can now claim, and the numerous high-numbered RE50218 claims (fragments at claims 23, 24, 25 … 50) appear to be added dependent claims reciting narrower parameters (osmolality ≈290 mOsm/kg, pH ≈8.3, 0.045–0.09% bromfenac, viscosity measured with a Brookfield cone-and-plate DV‑II+ spindle CP‑52 at 6 rpm).

The '999 claim 1 (the "parent" of RE50218's composition claims), verbatim from the '999 patent:

"1. A topical ophthalmic composition formulated for application to the eye, said composition comprising a therapeutically effective amount of bromfenac and a flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer, wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5."
(https://patentimages.storage.googleapis.com/e6/1f/df/bf2e42cd27caba/US8778999.pdf; claim 1 also reproduced in the D.N.J. opinion at https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2018cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/0.pdf)

RE50218 claim fragments confirm the same architecture plus narrowing dependents, e.g.:

"23. The ophthalmic composition of claim 1, wherein the composition has an osmolality from about 10 mOsm/kg to 400 mOsm/kg."
"24. The ophthalmic composition of claim 1, wherein the composition has an osmolality of about 290 mOsm/kg and a pH of about 8.3."
"50. … the flowable mucoadhesive polymer is in an amount of about 0.5% to about 1.5% by weight of the composition; the composition comprises from about 0.045% to 0.09% bromfenac by weight of the composition, and wherein the viscosity is measured with a Brookfield cone and plate viscosity DV‑II+ with the spindle No. [CP‑52]…"
(https://www.drugpatentwatch.com/p/patent-claims/RE50218)

2. The prior art on this record, grouped by function

A. The delivery-system art (the vehicle limitations)

B. The drug art

C. The "additional medicament" / combination art

Bowman I and US 7,056,893 both expressly contemplate additional medicaments; the record also cites AzaSite® (azithromycin 1%, DuraSite vehicle, approved 2007) and Besivance® PIs, demonstrating the vehicle had already been commercialized with an anti-infective, and Shulman et al. (1996) on steroid–antibiotic combinations for blepharitis/conjunctivitis.

3. Obviousness combinations

Combination A — Bowman I (US 6,159,458) alone (KSR single-reference obviousness)

This is the strongest combination, and it is the combination actually litigated against the parent '999 patent.

Motivation to modify / select bromfenac (why a POSITA would do it):

• Recognized problem with a known solution. Xibrom® was a commercial 0.09% BID bromfenac drop; Bucci 2008 taught that its aqueous-humor levels decay at trough relative to ketorolac. Bowman I holds itself out as delivering sustained release of a water-soluble medicament in drop form using polycarbophil. The "leap" is selecting bromfenac as the medicament — a species within Bowman I's disclosed genus.
• The art taught the vehicle was drug-agnostic. Bowman I does not limit itself to timolol; it claims water-soluble, lipophilic (log P ≥ 2.0) medicaments and class-lists anti-inflammatory agents. Bromfenac (brominated amfenac; free-acid form pKa ~4, administered as the sodium salt at pH ~8.3) is water-soluble at the vehicle's pH and highly lipophilic — squarely within that disclosure.
• The mechanism was known in the ophthalmic literature. Lehr 1994 (polycarbophil enhanced ocular penetration of a hydrophilic drug in pigmented rabbits) and the mucoadhesion reviews supply the reason to expect increased aqueous-humor exposure — which is precisely the benefit RE50218 asserts.
• Commercial incentive. The litigation record reflects unrebutted expert testimony that "your biggest motivation once there's a [twice-daily] product is to get the first [once-daily] product," and that bromfenac's potency made it the obvious candidate among the five then-marketed ophthalmic NSAIDs (flurbiprofen and diclofenac had already been combined with polycarbophil; ketorolac/diclofenac stung; nepafenac required shaking). That is KSR-style market-pressure motivation.
• No technical hurdle. Unlike azithromycin (the subject of the InSite Vision v. Sandoz litigation, where aqueous instability of the drug supplied a non-obviousness rationale), bromfenac was already formulated as a stable aqueous ophthalmic solution at pH ~8.3 — at or near the claimed pH range — so stability/insolubility could not be asserted as a barrier.

Combination B — Ogawa (US 4,910,225) + Davis (US 5,192,535) [or Bowman I]

• Ogawa supplies bromfenac and its ophthalmic anti-inflammatory use; Davis supplies the polycarbophil/DuraSite ophthalmic suspension platform with drop-form viscosity, 10–400 mOsm osmolality, and in-situ gelling/sustained release.
• Motivation: both references are in the same field (ophthalmic anti-inflammatory therapy / ophthalmic drug delivery); Davis expressly frames its system as being "formulated with an ophthalmic medicament … into solutions or suspensions." Combining a known NSAID with a known sustained-release ophthalmic vehicle to reduce dosing frequency is the archetypal predictable combination; Bowman & Patel 1995 and the AzaSite® commercial product (2007) supplied the reasonable expectation of success for the vehicle.

Combination C — Xibrom® PI + Davis ('535) or Bowman I + Ahuja et al., Topical Ocular Delivery of NSAIDs, 10 AAPS J. 229 (2008)

• Ahuja 2008 (a review of topical ophthalmic NSAID delivery, in the RE50218 citation list) plus Xibrom's BID label supply (i) the problem (poor NSAID retention/trough coverage) and (ii) the class-level solution (mucoadhesive polymer vehicles). Davis/Bowman I supply the specific vehicle chemistry.
• This is the combination most naturally framed as "obvious to try" — a finite, identified set of ophthalmic vehicles (polycarbophil/Carbopol, cellulose derivatives, PVP, poloxamer gels) applied to a known drug.

Combination D — Any of A–C + Acular® labeling and/or Waterbury 2006 / Bucci 2008 (for the ketorolac-dependent claims)

• The claims reciting "a therapeutically effective amount of ketorolac" (the RE50218 analogue of '999 claim 2) require only selecting a second, commercially available ophthalmic NSAID. Bowman I and US 7,056,893 both expressly permit additional medicaments; Waterbury 2006 and Bucci 2008 compare ketorolac and bromfenac directly, giving a POSITA both reason and expectation of additive anti-inflammatory effect.
• The claimed ketorolac ranges (0.01–1%; 0.4–0.5%) overlap the commercial Acular LS 0.4% product — a range the art already embodied.

Combination E — For the steroidal / antibacterial / "additional active" claims (and the specification's bromfenac + dexamethasone, + tobramycin, + doxycycline examples)

• Motivation comes from (i) Bowman I's and US 7,056,893's express "additional medicaments" teachings; (ii) AzaSite®/Besivance® PIs showing the DuraSite-type vehicle already carried an anti-infective; (iii) Shulman 1996 (steroid–antibiotic combinations for ocular surface inflammation). These claims stand or fall with the independent claim, since the gist of the invention — bromfenac in a polycarbophil vehicle — is unchanged by adding a second known ocular agent.

4. The narrow dependent claims (the likely reissue battleground)

The new RE50218 dependents appear to recite: pH ≈8.3; osmolality ≈290 mOsm/kg; bromfenac 0.045–0.09%; polycarbophil 0.5–1.5% (or 0.8–1.0%); viscosity ≈1,000–3,400 cps by Brookfield cone-and-plate DV‑II+ CP‑52 at 6 rpm. Each is a routine optimization of values already taught: Davis discloses 10–400 mOsm and the drop-form viscosity window; Bowman I discloses the pH and the 1,000–3,400 cps range with the identical instrument/spindle; Xibrom supplies 0.09% and the ~0.045% half-strength is nothing more than halving a known active strength; 0.9% polycarbophil sits inside both the '535 and Bowman I ranges. Under KSR, "'[a] result-effective variable' … would have been obvious to try," and no criticality is apparent from the specification (the specification's own Example 1 uses 0.9% polycarbophil, pH 8.3, 290 mOsm across three different strengths).

5. Objective indicia — what the patentee would argue, and how it cuts

For the patentee:

• Unexpected results. RE50218 asserts "unexpectedly … high absorption and retention of bromfenac by the aqueous humor," supported by FIGS 1A/1B; the FDA review of NDA 206911 independently documents roughly 4-fold higher sclera, choroid, and aqueous-humor levels vs Bromday for ISV-303, with no added ocular toxicity (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206911Orig1s000SumR.pdf). A patentee would characterize this as superior to what Bowman I's timolol-oriented disclosure would predict.
• Long-felt need / commercial success. Once-daily ophthalmic NSAID therapy was a recognized goal; BromSite is the commercial embodiment.
• Teaching away / technical skepticism, by analogy to InSite Vision v. Sandoz (Fed. Cir. 14‑1065), where the district court found a DuraSite-based azithromycin combination non-obvious in the face of water-instability concerns about that drug — and where the court stressed that "Carbopol" ≠ polycarbophil and that mere availability of the vehicle did not make the combination obvious.

Against the patentee (why these are weaker here):

• The advantage is one of degree, not kind. Bowman I's stated object is sustained release from a polycarbophil vehicle for a water-soluble medicament; Lehr 1994 had already shown polycarbophil increases ocular penetration in the pigmented rabbit. A 2–4× exposure improvement is the expected directional result of the disclosed mechanism, and the case law requires unexpected results to be qualitative or otherwise disproportionate.
• No technical hurdle to overcome. The InSite/Sandoz non-obviousness rationale rested on azithromycin's aqueous instability and the differences between Carbopol 934P and polycarbophil. Bromfenac in water at pH ~8.3 was already a marketed product, so the "would it work?" objection is absent.
• The '999 opinion. In InSite Vision litigation, Civil Action No. 3:18‑cv‑02213‑FLW‑TJB (D.N.J., opinion filed 2021‑09‑30), the court found '999 claims 1, 3, 9, 10, 11 and 16 obvious over Bowman I alone and declined to reach the defendants' other combinations (https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2018cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/0.pdf). That opinion was vacated on 2022‑02‑08 and the case dismissed with prejudice on 2022‑02‑09 (both listed in the RE50218 citation list), so it has no preclusive or precedential force — but note the timing: the reissue application was filed 2022‑04‑22, weeks after the vacatur/dismissal. It is at minimum a roadmap of how an invalidity challenge to these claims would be framed, and the RE50218 claim set (with its added parameter dependents) reads like a response to exactly that attack.

6. Bottom line

• The independent composition/system claims (RE50218 counterparts of '999 claim 1) are highly vulnerable under §103: Bowman I (US 6,159,458) discloses every element except the identity of the NSAID, and its medicament genus (which expressly includes anti-inflammatory agents, and any lipophilic medicament with log P ≥ 2.0) encompasses bromfenac. Motivation is supplied by Xibrom's BID profile and trough deficiencies (Bucci 2008), the known mucoadhesive-polymer mechanism (Davis '535; Lehr 1994; Ahuja 2008), and market pressure toward once-daily dosing, with a reasonable expectation of success and no technical hurdle to overcome. Ogawa ('225) + Davis ('535) is the conventional two-reference fallback.
• The narrow dependents (pH 8.3; 290 mOsm/kg; 0.045–0.09%; 0.5–1.5%/0.8–1.0% polycarbophil; 1,000–3,400 cps by DV‑II+/CP‑52) are routine optimizations lying within the express ranges of Davis and Bowman I; they are obvious absent evidence of criticality.
• Ketorolac and other combination claims are obvious over the same art in view of Bowman I's/US 7,056,893's "additional medicament" teachings and the commercial Acular® labeling.
• The strongest patentee rebuttal is the asserted (and FDA-corroborated) 2–4× ocular exposure gain, but it is likely an advantage in kind from a mechanism already disclosed; it is materially weaker than the azithromycin/DuraSite non-obviousness rationale upheld in InSite Vision v. Sandoz, because bromfenac was stable and already sold as an aqueous drop at the claimed pH.

Unverified / flagged items: the complete RE50218 claim text (not present in the page text I was given; claim fragments only); the RE50218↔'999 reissue parentage (inference from title/inventors/priority/assignee and Orange Book history, not from the reissue certificate); the specific contents of several reference-list entries I did not open, including US‑5475034‑A, US‑5110493‑A, US‑5188826‑A, US‑5221696‑A, US‑5332582‑A, US‑5340572‑A, US‑5414011‑A, US‑5558876‑A, US‑5814655‑A, US‑6060463‑A, US‑6265444‑B1 and WO‑0130380‑A2 — I have cited them only as appearing on the record, without attributing disclosure content to them.